Annual Cash & Cash Equivalents
$1.30 M
+$528.00 K+68.39%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual cash & cash equivalents is currently $1.30 million, with the most recent change of +$528.00 thousand (+68.39%) on 31 December 2023. During the last 3 years, it has fallen by -$36.53 million (-96.56%). BCLI annual cash & cash equivalents is now -96.56% below its all-time high of $37.83 million, reached on 31 December 2020.BCLI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$168.00 K
-$3.30 M-95.16%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly cash and cash equivalents is currently $168.00 thousand, with the most recent change of -$3.30 million (-95.16%) on 30 September 2024. Over the past year, it has dropped by -$1.05 million (-86.25%). BCLI quarterly cash and cash equivalents is now -99.56% below its all-time high of $37.83 million, reached on 31 December 2020.BCLI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +68.4% | -86.3% |
| 3 y3 years | -96.6% | -99.3% |
| 5 y5 years | +38.0% | -92.0% |
BCLI Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -96.6% | +68.4% | -99.3% | at low |
| 5 y | 5 years | -96.6% | +142.5% | -99.6% | at low |
| alltime | all time | -96.6% | >+9999.0% | -99.6% | >+9999.0% |
Brainstorm Cell Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $168.00 K(-95.2%) |
| June 2024 | - | $3.47 M(+345.3%) |
| Mar 2024 | - | $779.00 K(-40.1%) |
| Dec 2023 | $1.30 M(+68.4%) | $1.30 M(+6.4%) |
| Sept 2023 | - | $1.22 M(+123.8%) |
| June 2023 | - | $546.00 K(-73.0%) |
| Mar 2023 | - | $2.02 M(+161.8%) |
| Dec 2022 | $772.00 K(-95.9%) | $772.00 K(-81.4%) |
| Sept 2022 | - | $4.14 M(-54.0%) |
| June 2022 | - | $9.01 M(-40.6%) |
| Mar 2022 | - | $15.15 M(-19.6%) |
| Dec 2021 | $18.86 M(-50.2%) | $18.86 M(-26.6%) |
| Sept 2021 | - | $25.70 M(-15.9%) |
| June 2021 | - | $30.57 M(-14.9%) |
| Mar 2021 | - | $35.93 M(-5.0%) |
| Dec 2020 | $37.83 M(+6957.6%) | $37.83 M(+52.7%) |
| Sept 2020 | - | $24.77 M(+103.8%) |
| June 2020 | - | $12.15 M(-2.5%) |
| Mar 2020 | - | $12.47 M(+2226.7%) |
| Dec 2019 | $536.00 K(-43.1%) | $536.00 K(-74.4%) |
| Sept 2019 | - | $2.10 M(+86.1%) |
| June 2019 | - | $1.13 M(-65.2%) |
| Mar 2019 | - | $3.24 M(+243.7%) |
| Dec 2018 | $942.00 K(-62.1%) | $942.00 K(+35.2%) |
| Sept 2018 | - | $697.00 K(-69.2%) |
| June 2018 | - | $2.26 M(-30.3%) |
| Mar 2018 | - | $3.25 M(+30.7%) |
| Dec 2017 | $2.48 M(+353.9%) | $2.48 M(+0.8%) |
| Sept 2017 | - | $2.46 M(-57.4%) |
| June 2017 | - | $5.78 M(+857.6%) |
| Mar 2017 | - | $604.00 K(+10.4%) |
| Dec 2016 | $547.00 K(+27.8%) | $547.00 K(-42.7%) |
| Sept 2016 | - | $955.00 K(+1.2%) |
| June 2016 | - | $944.00 K(-57.3%) |
| Mar 2016 | - | $2.21 M(+417.1%) |
| Dec 2015 | $428.00 K(-89.9%) | $428.00 K(-39.7%) |
| Sept 2015 | - | $710.00 K(-45.4%) |
| June 2015 | - | $1.30 M(-62.8%) |
| Mar 2015 | - | $3.49 M(-17.8%) |
| Dec 2014 | $4.25 M(+21.4%) | $4.25 M(-52.6%) |
| Sept 2014 | - | $8.97 M(-20.8%) |
| June 2014 | - | $11.33 M(+274.2%) |
| Mar 2014 | - | $3.03 M(-13.6%) |
| Dec 2013 | $3.50 M | $3.50 M(+964.7%) |
| Sept 2013 | - | $329.00 K(-56.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2013 | - | $755.00 K(-59.6%) |
| Mar 2013 | - | $1.87 M(+41.8%) |
| Dec 2012 | $1.32 M(-31.5%) | $1.32 M(-72.5%) |
| Sept 2012 | - | $4.78 M(+467.4%) |
| June 2012 | - | $843.00 K(-26.4%) |
| Mar 2012 | - | $1.15 M(-40.5%) |
| Dec 2011 | $1.92 M(+1967.7%) | $1.92 M(-19.5%) |
| Sept 2011 | - | $2.39 M(-17.6%) |
| June 2011 | - | $2.90 M(-20.9%) |
| Mar 2011 | - | $3.66 M(+3839.8%) |
| Dec 2010 | $93.00 K(+9200.0%) | $93.00 K(-87.6%) |
| Sept 2010 | - | $750.00 K(+3.4%) |
| June 2010 | - | $725.00 K(-40.3%) |
| Mar 2010 | - | $1.22 M(>+9900.0%) |
| Dec 2009 | $1000.00(-50.0%) | $1000.00(-50.0%) |
| Sept 2009 | - | $2000.00(0.0%) |
| June 2009 | - | $2000.00(0.0%) |
| Mar 2009 | - | $2000.00(0.0%) |
| Dec 2008 | $2000.00(-97.7%) | $2000.00(-90.5%) |
| Sept 2008 | - | $21.00 K(-63.2%) |
| June 2008 | - | $57.00 K(-33.7%) |
| Dec 2007 | $86.00 K(+43.3%) | $86.00 K(-64.3%) |
| Sept 2007 | - | $241.00 K(+5925.0%) |
| June 2007 | - | $4000.00(-86.7%) |
| Mar 2007 | - | $30.00 K(-43.4%) |
| Dec 2006 | $60.00 K(-79.3%) | - |
| Sept 2006 | - | $53.00 K(-81.7%) |
| June 2006 | - | $289.50 K(-0.2%) |
| Mar 2006 | - | $290.20 K(+234.7%) |
| Mar 2006 | $290.20 K(-44.9%) | - |
| Dec 2005 | - | $86.70 K(-71.2%) |
| Sept 2005 | - | $301.00 K(-1.5%) |
| June 2005 | - | $305.50 K(-42.0%) |
| Mar 2005 | $526.50 K(+5165.0%) | $526.50 K(+91.5%) |
| Dec 2004 | - | $274.90 K(+403.5%) |
| Sept 2004 | - | $54.60 K(-19.5%) |
| June 2004 | - | $67.80 K(+1406.7%) |
| Dec 2003 | - | $4500.00(-30.8%) |
| Sept 2003 | - | $6500.00(-32.3%) |
| June 2003 | - | $9600.00(-4.0%) |
| Mar 2003 | $10.00 K(-72.3%) | $10.00 K(-33.3%) |
| Dec 2002 | - | $15.00 K(-32.1%) |
| Sept 2002 | - | $22.10 K(-36.1%) |
| June 2002 | - | $34.60 K |
| Mar 2002 | $36.10 K | - |
FAQ
- What is Brainstorm Cell Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual cash & cash equivalents year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Brainstorm Cell Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of BCLI is $1.30 M
What is the all time high annual cash & cash equivalents for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual cash & cash equivalents is $37.83 M
What is Brainstorm Cell Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, BCLI annual cash & cash equivalents has changed by +$528.00 K (+68.39%)
What is Brainstorm Cell Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BCLI is $168.00 K
What is the all time high quarterly cash and cash equivalents for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly cash and cash equivalents is $37.83 M
What is Brainstorm Cell Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, BCLI quarterly cash and cash equivalents has changed by -$1.05 M (-86.25%)